Project Grant R01CA293366
Award Date
7/15/24
Completion Date
6/30/29
Dollars Obligated
$628K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
The federal Project Grant award from the National Cancer Institute (NCI) provides $159,803 over a period of 5 years (9/3/2024 - 8/31/2029) to support the "INTEGRATIVE MULTIOMICS AND CLINICAL LABORATORY TRANSLATION FOR ADVANCED, RARE, AND PEDIATRIC CANCERS" project. The award aims to incorporate emerging genomic, transcriptomic, epigenomic and proteomic technologies to analyze advanced, rare, and pediatric cancers, and translate the results into clinically actionable information through...
This Project Grant award of $2,044,728 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports a comprehensive investigation into the genetic underpinnings of pediatric cancers. The research team at St. Jude Children's Research Hospital will leverage existing genetic datasets on over 43,000 pediatric cancer cases spanning more than 25 cancer subtypes. The key objectives are to: 1) Conduct a systematic search for common genetic...
This federal Project Grant award, valued at $398,207.00 and provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), aims to develop and test a multilevel intervention to improve interdisciplinary communication quality in low-resource pediatric oncology hospitals. The key products and services to be delivered under this five-year grant include: Conducting a cross-sectional social network analysis across 20 hospitals to identify the relationship between...
This $695,464 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Boston Children's Hospital aims to integrate genomic and epigenomic data to pinpoint causal genetic variants associated with childhood B-cell acute lymphoblastic leukemia (B-ALL) risk. The key products and services to be delivered under this 5-year project include: Conducting a large, multi-ancestry genome-wide association study (GWAS) of childhood B-ALL, followed by statistical...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to Electronic Biosciences, Inc., a small biotechnology company in San Diego, CA. The funding will support the development of a novel nanopore-based sequencing approach to accurately characterize repetitive DNA sequences, which are challenging to analyze using current sequencing-by-synthesis technology. This capability will enable improved cancer...
This Project Grant award, valued at $544,250 and provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research by the University of North Carolina at Chapel Hill aimed at improving diagnosis and treatment for lymphoproliferative disorders (LPDs) among people living with HIV in Malawi. The key objectives of this 5-year project are to: 1) assess barriers to timely LPD diagnosis in Malawi, 2) comprehensively describe the clinical...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $1,197,216 to St. Jude Children's Research Hospital to advance the scientific understanding and treatment of pineoblastoma, a rare and aggressive pediatric brain tumor. The key objectives are to: (1) leverage single-cell transcriptome data and developmental atlases to delineate the cellular origins and molecular drivers of distinct...
The National Cancer Institute (NCI) awarded a $602,486 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Health Research, Inc., a not-for-profit research organization based in Buffalo, NY. The grant aims to explore the feasibility of targeting retrotransposons, or mobile genetic elements, as a novel approach to treating refractory pediatric cancers, with a primary focus on high-risk neuroblastoma. The project seeks to comprehensively characterize retrotransposon activity...
This Project Grant award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353) supports research to implement optical genome mapping (OGM) as a first-line diagnostic approach for identifying structural variants in pediatric brain tumors. The $699,080 award to Ann & Robert H. Lurie Children's Hospital of Chicago will validate OGM as a CLIA/CAP certified test and utilize it to discover novel pathogenic...
The University of North Carolina at Charlotte received a three-year Project Grant totaling $900,538 from the National Cancer Institute within the Department of Health and Human Services. The grant falls under the Cancer Detection and Diagnosis Research program (CFDA 93.394), which aims to improve cancer screening, early detection, and diagnostic techniques. The university will develop a multimodal nanoparticle platform for the efficient treatment of triple-negative breast cancer. Researchers...